Acquisition of androgen independence by human prostate epithelial cells during arsenic-induced malignant transformation

Environmental Health Perspectives

Volumn 113, Issue 9, 2005, Pages 1134-1139

  Benbrahim Tallaa, Lamia ^a   Webber, Mukta M ^b,c   Waalkes, Michael P ^a  

^a National Cancer Institute   (United States)

^b MICHIGAN STATE UNIVERSITY   (United States)

^c MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

Androgen independent; AR; Arsenic; Cancer progression; Malignant transformation; Prostate

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; ANDROSTANOLONE; ARSENIC; EPIDERMAL GROWTH FACTOR; ESTRADIOL; HYPOPHYSIS EXTRACT; PROSTATE SPECIFIC ANTIGEN; STEROID HORMONE;

ARTICLE; CANCER CELL CULTURE; CELL IMMORTALIZATION; CELL PROLIFERATION; CELL STIMULATION; CELL TRANSFORMATION; CONTROLLED STUDY; CULTURE MEDIUM; DOWNSTREAM PROCESSING; GENE EXPRESSION; HORMONAL REGULATION; HORMONE ACTION; HUMAN; HUMAN CELL; KERATINOCYTE; LONG TERM EXPOSURE; MALE; MALIGNANT TRANSFORMATION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE EPITHELIUM; SIGNAL TRANSDUCTION; TUMOR GROWTH; UPREGULATION;

ANDROGEN ANTAGONISTS; ANDROGENS; ANIMALS; ARSENIC; CELL LINE; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; DIHYDROTESTOSTERONE; EPIDERMAL GROWTH FACTOR; EPITHELIAL CELLS; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FLUTAMIDE; GENE EXPRESSION REGULATION; HUMANS; MALE; MICE; PITUITARY GLAND; PROSTATE; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; RNA, MESSENGER;

BOVINAE;

EID: 25844483806     PISSN: 00916765     EISSN: None     Source Type: Journal    
DOI: 10.1289/ehp.7832     Document Type: Article

References (54)

1. Achanzar WE, Brambila EM, Diwan BA, Webber MM, Waalkes MP. 2002. Inorganic arsenite induced malignant transformation of human prostate epithelial cells. J Natl Cancer Inst 94:1888-1891.
2. Arnold JT, Isaacs JT. 2002. Mechanisms involved in the progression of androgen independent prostate cancers: it is not only the cancer cell's fault. Rev Endocr Relat Cancer 9:61-73.
3. Bakin RE, Gioeli D, Bissonette EA, Weber MJ. 2003a. Attenuation of Ras signaling restores androgen sensitivity to hormone-refractory C4-2 prostate cancer cells. Cancer Res 63:1975-1980.
4. Bakin RE, Gioeli D, Sikes RA, Bissonette EA, Weber MJ. 2003b. Constitutive activation of the Ras/mitogen-activated protein kinase signaling pathway promotes androgen hypersensitivity in LNCaP prostate cancer cells. Cancer Res 63:1981-1989.
5. Bello D, Webber MM, Kleinman HK, Wartinger DD, Rhim JS. 1997. Androgen responsive adult human prostatic epithelial cell lines immortalized by human papillomavirus 18. Carcinogenesis 18:1215-1223.
6. Benbrahim-Tallaa L, Waterland RA, Styblo M, Achanzar WE, Webber MM, Waalkes MP. In press. Molecular events associated with arsenic induced malignant transformation of human prostatic epithelial cells: aberrant genomic DNA methylation and oncogene activation. Toxicol Appl Pharmacol.
7. Block JL, Block NL, Lokeshwar BL. 1996. Modulation of aromatase activity by growth factors in an androgen sensitive human prostate cancer cell line, LNCaP. Cancer Lett 102:167-172.
8. Bonkhoff H, Stein U, Aumuller G, Remberger K. 1996. Differential expression of 5 alpha-reductase isoenzymes in the human prostate and prostatic carcinomas. Prostate 29:261-267.
9. Bosland MC. 2000. The role of steroid hormones in prostate carcinogenesis. J Natl Cancer Inst Monogr 27:39-66.
10. Chen CJ, Wang CJ. 1990. Ecological correlation between arsenic levels in well water and age adjusted mortality from malignant neoplasms. Cancer Res 50:5470-5474.
11. Comuzzi B, Lambrinidis L, Rogatsch H, Godoy-Tundidor S, Knezevic N, Krhen I, et al. 2003. The transcriptional co-activator cAMP response element-binding protein-binding protein is expressed in prostate cancer and enhances androgen- and anti-androgen-induced androgen receptor function. Am J Pathol 162:233-241.
12. Crawford ED. 2003. Epidemiology of prostate cancer. Urology 62(suppl 1):3-12.
13. Culig Z, Hobisch A, Cronauer MV, Radmayr C, Trapman J, Hittmair A, et al. 1994. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res 54:5474-5478.
14. Curtis SW, Shi H, Teng C, Korach KS. 1997. Promoter and species specific differential estrogen-mediated gene transcription in the uterus and cultured cells using structurally altered agonists. J Mol Endocrinol 18:203-211.
15. Delos S, Carsol JL, Ghazarossian E, Raynaud JP, Martin PM. 1995. Testosterone metabolism in primary culture of human prostate epithelial cells and fibroblasts. J Steroid Biochem Mol Biol 55:375-383.
16. Deutsch E, Maggiorella L, Eschwege P, Bourhis J, Soria JC, Abdulkarim B. 2004. Environmental, genetic, and molecular features of prostate cancer. Lancet Oncol 5:303-313.
17. Farnsworth WE. 1999. Estrogen in the ethiopathogenesis of BPH. Prostate 41:263-274.
18. Feldman BJ, Feldman D. 2001. The development of androgen-independent prostate cancer. Nat Rev Cancer 1:34-45.
19. Gleave M, Tolcher A, Miyake H, Nelson C, Brown B, Beraldi E, et al. 1999. Progression to androgen independence is delayed by adjuvant treatment with antisense Bcl-2 oligodeoxynucleotides after castration in the LNCaP prostate tumor model. Clin Cancer Res 5:2891-2898.
20. Grossmann ME, Huang H, Tindall DJ. 2001. Androgen receptor signaling in androgen refractory prostate cancer. J Natl Cancer Inst 93:1687-1697.
21. Harkonen PL, Makela SI. 2004. Role of estrogens in development of prostate cancer. J Steroid Biochem Mol Biol 92:297-305.
22. Igawa T, Lin FF, Lee MS, Karan D, Batra SK, Lin MF. 2002. Establishment and characterization of androgen-independent human prostate cancer LNCaP cell model. Prostate 50:222-235.
23. Kaefer M, Audia JE, Bruchovsky N, Goode RL, Hsiao KC, Leibovitch IY, et al. 1996. Characterization of type I 5 alpha-reductase activity in DU145 human prostatic adenocarcinoma cells. J Steroid Biochem Mol Biol 58:195-205.
24. Koivisto P, Kononen J, Palmberg C, Tammela T, Hyytinen E, Isola J, et al. 1997. Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res 57:314-319.
25. Konishi N, Nakaoka S, Hiasa Y, Kitahori Y, Ohshima M, Samma S, et al. 1993. Immunohistochemical evaluation of estrogen receptor status in benign prostatic hypertrophy and in prostate carcinoma and the relationship to endocrine therapy. Oncology 50:259-263.
26. Kyprianou N, Isaacs JT. 1988. Activation of programmed cell death in the rat ventral prostate. Endocrinology 122:552-562.
27. Lai JS, Brown LG, True LD, Hawley SJ, Etzioni RB, Higano CS, et al. 2004. Metastases of prostate cancer express estrogen receptor-beta. Urology 64:814-820.
28. Leav I, Lau KM, Adams JY, McNeal JE, Taplin ME, Wang J, et al. 2001. Comparative studies of the estrogen receptors beta and alpha and the androgen receptor in normal human prostate glands, dysplasia, and in primary and metastatic carcinoma. Am J Pathol 159:79-92.
29. Lewis DR, Southwick JW, Ouellet-Hellstrom R, Rench J, Calderon RL. 1999. Drinking water arsenic in Utah: a cohort mortality study. Environ Health Perspect 107:359-365.
30. Linja MJ, Savinainen KJ, Tammela TL, Isola JJ, Visakorpi T. 2003. Expression of ERalpha and ERbeta in prostate cancer. Prostate 55:180-186.
31. Martin AW, Coffey DS. 1998. The molecular biology, endocrinology, and physiology of the prostate and seminal vesicles. In: Campbell's Urology (Walsh PC, Bretik A, Vaughan ED, Wein AJ, eds). Philadelphia:W.B. Saunders, 1381-1428.
32. Matzkin H, Soloway MS. 1992. Immunohistochemical evidence of the existence and localization of aromatase in human prostatic tissues. Prostate 21:309-314.
33. Negri-Cesi P, Colciago A, Poletti A, Motta M. 1999. 5alpha-reductase isozymes and aromatase are differentially expressed and active in the androgen-independent human prostate cancer cell lines DU145 and PC3. Prostate 41:224-232.
34. NTP. 2000. Ninth Report on Carcinogens. Research Triangle Park, NC:National Toxicology Program.
35. Occhiato EG, Guarna A, Danza G, Serio M. 2004. Selective non-steroidal inhibitors of 5 alpha reductase type 1. J Steroid Biochem Mol Biol 88:1-16.
36. Pott WA, Benjamin SA, Yang RS. 2001. Pharmacokinetics, metabolism, and carcinogenicity of arsenic. Rev Environ Contam Toxicol 169:1655-214.
37. Raghow S, Hooshdaran MZ, Katiyar S, Steiner MS. 2002. Toremifene prevents prostate cancer in the transgenic adenocarcinoma of mouse prostate model. Cancer Res 62:1370-1376.
38. Robertson CN, Roberson KM, Padilla GM, O'Brien ET, Cook JM, Kim CS, et al. 1996. Induction of apoptosis by diethylstilbestrol in hormone-insensitive prostate cancer cells. J Natl Cancer Inst 88:908-917.
39. Rossman TG, Uddin AN, Burns FJ. 2004. Evidence that arsenite acts as a cocarcinogen in skin cancer. Rev Toxicol Appl Pharmacol 198:394-404.
40. Simpson E, Rubin G, Clyne C, Robertson K, O'Donnell L, Davis S, et al. 1999. Local estrogen biosynthesis in males and females. Endocr Relat Cancer 6:131-137.
41. Suzuki H, Ueda T, Ichikawa T, Ito H. 2003. Androgen receptor involvement in the progression of prostate cancer. Rev Endocr Relat Cancer 10:209-216.
42. Taplin ME, Balk SP. 2004. Androgen receptor: a key molecule in the progression of prostate cancer to hormone independence. J Cell Biochem 91:483-490.
43. Taplin ME, Bubley GJ, Ko YJ, Small EJ, Upton M, Rajeshkumar B, et al. 1999. Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. Cancer Res 59:2511-2515.
44. Thomas LN, Douglas RC, Vessey JP, Gupta R, Fontaine D, Norman RW, et al. 2003. 5alpha reductase type1 immunostaining is enhanced in some prostate cancers compared with benign prostatic hyperplasia epithelium. J Urol 170:2019-2025.
45. Tilley WD, Buchanan G, Hickey TE, Bentel JM. 1996. Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independence. Clin Cancer Res 2:277-285.
46. Visakorpi T, Hyytinen E, Koivisto P, Tanner M, Keinanen R, Palmberg C, et al. 1995. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet 9:401-406.
47. Waalkes MP, Ward JM, Diwan BA. 2004. Induction of tumors of the liver, lung, ovary and adrenal in adult mice after brief maternal gestational exposure to inorganic arsenic: promotional effects of postnatal phorbol ester exposure on hepatic and pulmonary, but not dermal cancers. Carcinogenesis 25:133-141.
48. Webber MM, Bello D, Kleinman HK, Hoffman MP. 1997. Acinar differentiation by non malignant immortalized human prostatic epithelial cells and its loss by malignant cells. Carcinogenesis 18:1225-1231.
49. Weber MJ, Gioeli D. 2004. Ras signaling in prostate cancer progression. J Cell Biochem 91:13-25.
50. Weihua Z, Warner M, Gustafsson JA. 2002. Estrogen receptor beta in the prostate. Mol Cell Endocrinol 193:1-5.
51. Westin P, Bergh A. 1998. Apoptosis and other mechanisms in androgen ablation treatment and androgen independent progression of prostate cancer. Rev Cancer Detect Prev 22:476-484.
52. Yeap BB, Krueger RG, Leedman PJ. 1999. Differential post-transcriptional regulation of androgen receptor gene expression by androgen in prostate and breast cancer cells. Endocrinology 140:3282-3291.
53. Yeh S, Lin HK, Kang HY, Thin TH, Lin MF, Chang C. 1999. From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells. Proc Natl Acad Sci USA 96:5458-5463.
54. Zegarra-Moro OL, Schmidt LJ, Huang H, Tindall DJ. 2002. Disruption of androgen receptor function inhibits proliferation of androgen-refractory prostate cancer cells. Cancer Res 62:1008-1013.